← Leaderboards
Jay Evans
University Of Montana
$43,101,450
Attributed
$43,101,450
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $9.4M · FY2019–25$10M$7.5M$5M$2.5M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$43,101,450 · 4
By mechanism
N01$43,101,450 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of Montana
Same institution · by research overlap
- Dan Drecktrah$1,516,125
- Patrick R Secor$6,304,071
- Kendal Ryter$868,177
Others in their field
Other Emerging Leaders on “Adjuvant”
- Ted Ross · University Of Georgia$68,763,143
- Valerie Fremont · Quality Biological, Inc.$19,261,930
- Aaron Esser-Kahn · University Of Chicago$13,698,058
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$10,000,000
- Garcia-Sastre Adolfo · Icahn School Of Medicine At Mount Sinai$8,560,974
- Lisa Morici · Tulane University Of Louisiana$8,296,098
Research focus
AdjuvantVaccinesVaccine AdjuvantContractorFormulationAntigensImmunogenicityPathogenLigandsLibrariesCellsProgramsVaccine EvaluationPharmaceutical ChemistryInvestigationSynthetic PeptideInfluenza Virus VaccineSideInfectionInterleukin-1 ReceptorsEfficacy StudySmall MoleculeMycobacterium TuberculosisImmunity
Grant awards (19)
DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM$1,641,451
N01 · FY2025 · AI · contact PI
Identification of Novel Syk/Raf-1 Mediated CLR Ligands as Vaccine Adjuvants$1,561,142
N01 · FY2025 · AI · contact PI
DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM$5,504,851
N01 · FY2024 · AI · contact PI
Identification of Novel Syk/Raf-1 Mediated CLR Ligands as Vaccine Adjuvants$1,637,656
N01 · FY2024 · AI · contact PI
Development of an Optimized Adjuvanted TB Vaccine$358,674
N01 · FY2024 · AI · contact PI
Development of an Optimized Adjuvanted TB Vaccine$253,399
N01 · FY2024 · AI · contact PI
DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM$2,419,904
N01 · FY2023 · AI · contact PI
Discovery of novel synthetic IL-1 adjuvants$2,223,085
N01 · FY2023 · AI · contact PI
Discovery of novel synthetic IL-1 adjuvants$2,613,001
N01 · FY2022 · AI · contact PI
Development of an Optimized Adjuvanted TB Vaccine$2,076,197
N01 · FY2022 · AI · contact PI
Characterize and optimize adjuvants to test monkeypox vaccines$1,599,006
N01 · FY2022 · AI · contact PI
Development of the INI-4001 and INI-2002 adjuvants within the context of a vaccine to prevent Lyme disease.$1,000,000
N01 · FY2022 · AI · contact PI
Adjuvant development in the context of seasonal and pandemic influenza$3,583,801
N01 · FY2021 · AI · contact PI
Discovery of novel synthetic IL-1 adjuvants$2,521,699
N01 · FY2021 · AI · contact PI
Adjuvant development in the context of seasonal and pandemic influenza$3,971,336
N01 · FY2020 · AI · contact PI
COVID - Spplement VACCINE ADJ DISCOVERY PROGRAM (VADP)$3,699,711
N01 · FY2020 · AI · contact PI
Discovery of novel synthetic IL-1 adjuvants$1,702,084
N01 · FY2020 · AI · contact PI
Adjuvant development in the context of seasonal and pandemic influenza$3,308,745
N01 · FY2019 · AI · contact PI
Discovery of novel synthetic IL-1 adjuvants$1,425,708
N01 · FY2019 · AI · contact PI